A Johns Hopkins study sharpens the link between youth cannabis use disorder and psychiatric diagnoses

What the research says

A new study from the Johns Hopkins Bloomberg School of Public Health finds that adolescents and young adults diagnosed with cannabis use disorder go on to receive psychiatric diagnoses at meaningfully higher rates than peers without CUD. The finding is consistent with — and adds longitudinal weight to — Yale’s 2024 work linking CUD to psychosis-spectrum and mood disorders, and with the Hopkins team’s previously published guidance that early-adolescence cannabis use is contraindicated for anyone with a family history of psychosis.

Pair that with the largest evidence review of medicinal cannabis to date — a 50+ trial, 45-year Australian analysis covered by NPR in March and ScienceDaily — which concluded there is little to no high-quality evidence that cannabis effectively treats anxiety, depression, or PTSD. Together the two findings push the field toward a clearer position: cannabis is not a benign or therapeutically interchangeable substitute for first-line mental health treatment, particularly for young people.

Why it matters

Twenty-four states and D.C. now allow adult recreational cannabis, and many more allow medical use. That legal landscape is moving faster than the evidence base it relies on. For families in those states — including Arizona — the practical question is no longer whether cannabis is legally available but whether it’s the right tool for a given mental-health concern. The current evidence says: rarely.

If a young person in your life is using cannabis daily and struggling with anxiety, sleep, or mood, an evidence-based clinical conversation is worth the time. Rize can help connect you to options.